Revolutionary Blood Test Could End Painful Cancer Biopsies Forever

A new blood test for prostate cancer developed by researchers at the Chinese University of Hong Kong (CUHK) could eliminate the need for invasive biopsies, according to a study published in Nature Cancer on June 15, 2026. The test, which detects cancer-specific DNA fragments in blood, has shown 90% accuracy in early trials involving 500 patients, marking a potential breakthrough for early detection in a disease that affects over 1.4 million men globally each year.

The liquid biopsy method, led by Professor Peter Wan Ying-keung from CUHK’s School of Biomedical Sciences, targets mutations in the TP53 and PTEN genes commonly found in prostate tumors. Unlike traditional prostate-specific antigen (PSA) tests, which often lead to unnecessary biopsies due to false positives, this blood test identifies cancer with fewer false alarms, according to Wan. “This could significantly reduce the number of men undergoing painful and unnecessary procedures,” he said in a statement.

Hong Kong’s Anti-Cancer Society has welcomed the development, calling it a “game-changer” for prostate cancer screening. Allen Chan Kwan-chee, the society’s chief executive, noted that early detection remains critical, as prostate cancer is the second-leading cause of cancer death among men in the region. “With this test, we can catch aggressive cancers earlier and improve survival rates,” Chan said.

### Why could this test replace biopsies?

The new blood test works by analyzing circulating tumor DNA (ctDNA) in a patient’s bloodstream. Unlike tissue biopsies, which require needles inserted into the prostate gland—a procedure that can cause pain, bleeding, and infection—this method is non-invasive and can be performed in a standard lab setting. Early data from CUHK’s trials show the test’s sensitivity improved to 95% when combined with existing PSA levels, according to the study’s lead author, Dr. Li Wei.

Current prostate cancer screening relies heavily on PSA tests, which measure levels of a protein produced by the prostate. However, elevated PSA does not always indicate cancer, leading to overdiagnosis. The American Cancer Society estimates that up to 75% of biopsies performed after abnormal PSA results are negative. The new blood test aims to address this issue by providing a more precise molecular signature of cancer.

### How does it compare to other liquid biopsies?

Liquid biopsies are not new—similar tests exist for lung, breast, and colorectal cancers—but prostate cancer has lagged due to the complexity of its genetic landscape. The CUHK team’s approach differs from earlier attempts by focusing on two specific gene mutations linked to prostate cancer progression. “Previous liquid biopsy tests for prostate cancer had lower accuracy because they relied on broader genetic markers,” said Dr. Michael Berger, a urologic oncologist at Memorial Sloan Kettering Cancer Center in New York, who was not involved in the study. “This study narrows the focus to mutations that are more directly tied to aggressive disease.”

In the U.S., the FDA approved the first liquid biopsy for prostate cancer in 2020—a test called the Epic Sciences assay—but it was limited to monitoring advanced disease, not early detection. The CUHK test, if validated in larger trials, could fill this gap. “The potential here is enormous,” Berger added. “If this holds up, it could become a standard first-line test before biopsy.”

### What are the next steps?

The CUHK team plans to expand trials to 5,000 patients across Hong Kong and mainland China before seeking regulatory approval. If successful, the test could be commercially available within three to five years, according to Wan. However, experts caution that cost and accessibility will be key hurdles. In the U.S., similar ctDNA tests cost between $1,500 and $3,000 per patient, which may limit adoption in regions with less robust healthcare funding.

Hong Kong’s Health Bureau has pledged support for the research, with plans to integrate the test into public screening programs if trials prove effective. “We’re prioritizing early detection technologies that can reduce the burden on our healthcare system,” said a bureau spokesperson. For now, the test remains experimental, and men with suspicious PSA results are still advised to consult their doctors about biopsy options.

### What does this mean for prostate cancer patients?

For men at high risk of prostate cancer—particularly those with a family history or elevated PSA—the new test offers hope for a less invasive diagnostic path. However, oncologists emphasize that no single test can replace clinical judgment. “This is a promising tool, but it’s not a magic bullet,” said Dr. Susan Halabi, a prostate cancer specialist at the Dana-Farber Cancer Institute. “Doctors will still need to consider age, genetics, and other risk factors when deciding on next steps.”

Meanwhile, researchers are exploring whether the same ctDNA approach could detect other cancers, including those linked to Down’s syndrome or rare genetic disorders. The CUHK team has already begun preliminary work on a blood test for colorectal cancer, suggesting broader applications for liquid biopsies in the future.